Clinical Report: Evaluation of Serum Farnesoid X Receptor (FXR) Levels

Overview

This clinical investigation evaluates serum FXR levels and their correlation with specific metabolic parameters, including glucose sensitivity and lipid profiles, in obesity. The findings suggest that FXR may play a significant role in the metabolic dysregulation associated with obesity.

Background

Obesity is a major global health issue, contributing to numerous comorbidities such as Type 2 Diabetes Mellitus and cardiovascular disease. Understanding the mechanisms underlying obesity is crucial for developing effective treatment strategies. FXR, a nuclear hormone receptor, is implicated in bile acid and cholesterol homeostasis, making it a potential therapeutic target in obesity management. Targeting FXR could lead to novel treatment strategies that improve metabolic health.

Data Highlights

No numerical data was provided in the source material.

Key Findings

• FXR is critical for bile acid and cholesterol homeostasis.
• Higher total bile acid levels correlate with increased BMI in obese individuals.
• FXR activation may improve glucose sensitivity and metabolic health in both human and animal studies.
• FXR antagonists have shown potential in alleviating obesity-related metabolic disorders in animal models.
• Dysregulation of FXR signaling is linked to the development of metabolic diseases.

Clinical Implications

The findings highlight the importance of FXR in obesity-related metabolic dysfunction, suggesting that targeting FXR may offer new therapeutic avenues. Clinicians should consider the role of bile acids and FXR in managing obesity and its comorbidities, potentially incorporating FXR-targeting therapies into treatment plans.

Conclusion

This study underscores the potential of FXR as a therapeutic target in obesity management, warranting further investigation into its role in metabolic regulation, particularly in human populations.

References

1. Ding et al., BMC Endocrine Disorders, 2026 -- Comparison of serum Farnesoid X Receptor (FXR) levels and their associations with obesity-related metabolic parameters: a clinical study
2. American Diabetes Association, 2026 -- The Obesity Association Publishes New Standards of Care Section on Obesity Medications
3. AASLD, 2023 -- Statement from AASLD: AASLD Acknowledges Withdrawal of Obeticholic Acid for Primary Biliary Cholangitis
4. Obesity Surgery — Effects of Fatty Acids on Diseases Related to Obesity and Significant Weight Loss
5. Obesity Surgery — Gastric Expression of FTO and MC4R in Patients Undergoing Sleeve Gastrectomy: Diagnostic Relevance Lacking Predictive Capacity for Weight Loss
6. The Journal of Clinical Endocrinology & Metabolism — Association of Fetuin B with Cytokine/Chemokine Activity and Insulin Pathways in Human Adipose Tissue and Plasma
7. The Journal of Clinical Endocrinology & Metabolism — Links Between Plasma and Fecal Metabolites and Body Mass Index Along with Body Fat Distribution in Pediatric Populations
8. The Obesity Association Publishes New Standards of Care Section on Obesity Medications | American Diabetes Association
9. Statement from AASLD: AASLD Acknowledges Withdrawal of Obeticholic Acid for Primary Biliary Cholangitis and Announces Upcoming Guideline Update | AASLD
10. Comparison of serum Farnesoid X Receptor (FXR) levels and their associations with obesity-related metabolic parameters: a clinical study | BMC Endocrine Disorders | Springer Nature Link